PALI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.28%

Insider Buying (Last 12 Months): $9,670.00

Insider Selling (Last 12 Months): $0.00

Palisade Bio Insider Trading History Chart

Palisade Bio Share Price & Price History

^$0.66

▼ -0.0208 (-3.06%)

As of 04/1/2025 03:51 PM ET

Days: 30 | 90 | 365

Palisade Bio Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/28/2024	Donald Allen Williams	Director	Buy	1,000	$4.86	$4,860.00	1,000
5/24/2024	John David Finley	CEO	Buy	1,000	$4.81	$4,810.00	8,437
1/31/2024	Donald Allen Williams	Director	Buy	666	$9.00	$5,994.00	2,000
9/27/2023	Donald Allen Williams	Director	Buy	1,333	$8.10	$10,797.30	1,333
9/27/2023	John David Finley	CEO	Buy	1,000	$8.10	$8,100.00	2,892
9/14/2023	Robert J. Trenschel	Director	Sell	20	$9.60	$192.00
9/13/2023	John David Finley	CEO	Buy	1,000	$9.90	$9,900.00	1,892
8/23/2022	John David Finley	CFO	Buy	490	$2.40	$1,176.00	8,616
8/16/2022	John David Finley	CFO	Buy	6,666	$3.75	$24,997.50	8,126
8/16/2022	Thomas Hallam	CEO	Buy	2,666	$3.75	$9,997.50	3,839

See Full Table

SEC Filings (Institutional Ownership Changes) for Palisade Bio (NASDAQ:PALI)

11.79% of Palisade Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Palisade Bio Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Cetera Investment Advisers	70,006	$0.12M	0.0%	N/A	2.531%
12/26/2024	JPMorgan Chase & Co.	8,200	$29K	0.0%	N/A	0.542%
8/15/2024	Armistice Capital LLC	27,858	$0.13M	0.0%	-96.1%	2.976%
11/14/2022	Altium Capital Management LP	5,643,007	$0.56M	0.2%	N/A	25.791%
10/27/2022	Sargent Investment Group LLC	670,000	$76K	0.0%	+179.2%	3.062%
7/26/2022	Sargent Investment Group LLC	240,000	$98K	0.0%	+84.6%	1.097%
2/14/2022	Altium Capital Management LP	333,954	$0.43M	0.1%	N/A	2.460%
11/12/2021	Sargent Investment Group LLC	105,000	$0.28M	0.1%	N/A	0.812%
11/9/2021	BlackRock Inc.	28,841	$76K	0.0%	+16.7%	0.223%
9/17/2021	Virtu Financial LLC	18,200	$74K	0.0%	N/A	0.160%
8/16/2021	State Street Corp	28,210	$0.12M	0.0%	N/A	0.978%
8/16/2021	Sabby Management LLC	52,500	$0.21M	0.0%	N/A	1.821%
8/13/2021	Renaissance Technologies LLC	145,300	$0.59M	0.0%	N/A	5.040%
8/13/2021	Altium Capital Management LP	1,824,894	$7.43M	1.7%	N/A	63.298%
8/13/2021	Geode Capital Management LLC	24,675	$100K	0.0%	N/A	0.856%
8/13/2021	Vanguard Group Inc.	237,811	$0.97M	0.0%	N/A	8.249%
8/12/2021	Private Advisor Group LLC	21,051	$86K	0.0%	N/A	0.730%
8/6/2021	HighTower Advisors LLC	16,666	$68K	0.0%	N/A	0.578%
7/31/2021	Strategic Wealth Designers	53,129	$0.22M	0.1%	N/A	1.845%

Data available starting January 2016

See Full Table

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Today's Range

Now: $0.66

$0.64

$0.68

50 Day Range

MA: $1.03

$0.68

$1.52

52 Week Range

Now: $0.66

$0.64

$9.65

Volume

47,358 shs

Average Volume

755,846 shs

Market Capitalization

$2.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Who are the company insiders with the largest holdings of Palisade Bio?: Palisade Bio's top insider investors include:
John David Finley (CEO)
Donald Allen Williams (Director)
Robert J Trenschel (Director)
Learn More about top insider investors at Palisade Bio.
Who are the major institutional investors of Palisade Bio?: Palisade Bio's top institutional shareholders include:
Cetera Investment Advisers — 2.53%
Learn More about top institutional investors of Palisade Bio stock.
Which major investors are buying Palisade Bio stock?: During the previous quarter, PALI stock was bought by institutional investors including:
Cetera Investment Advisers
Within the previous year, these company insiders have bought Palisade Bio stock:
John David Finley (CEO)
Donald Allen Williams (Director)
Learn More investors buying Palisade Bio stock.